| Identification | Back Directory | [Name]
P300/CBP-IN-3 | [CAS]
2299226-01-8 | [Synonyms]
P300/CBP-IN-3
CBP/p300-IN-3
1H-Benzimidazole-5-carboxamide, 2-[6-(diethylamino)-3-pyridinyl]-1-[(1-ethyl-1H-pyrazol-3-yl)methyl]-N-methyl-
6-(diethylamino)pyridin-3-yl]-1-[(1-ethyl-1H-pyra
zol-3-yl)methyl]-N-methyl-1H-1,3-benzodiazole-5-c
arboxamide | [Molecular Formula]
C24H29N7O | [MDL Number]
MFCD32201113 | [MOL File]
2299226-01-8.mol | [Molecular Weight]
431.53 |
| Chemical Properties | Back Directory | [density ]
1.23±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: 250 mg/mL (579.33 mM) | [form ]
Solid | [pka]
14.05±0.46(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
CBP/p300-IN-3, a p300/CBP histone acetyltransferase inhibitor, Compound 6, is sourced from patent WO 2019049061 A1[1]. | [References]
[1] Medina, et al. 5-(1H-Benzo[d]imidazol-2-yl)pyridin-2-amine and 5-(3H-imidazo[4,5-b]pyridin-6-yl)pyridin-2-amine derivatives as c-MYC and p300/CBP histone acetyltransferase inhibitors for treating cancer and their preparation. |
|
|